AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05730036
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab will be administered by IV infusion
Trial: NCT05730036
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide capsules will be administered by mouth (PO)
Trial: NCT05730036
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
Trial: NCT06356012
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
Trial: NCT05169112
Drug: Lupron Depot
RxNorm normalized name: Lupron Depot
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
Trial: NCT05940493
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT06489431
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
Trial: NCT06489431
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial known to inhibit DNA-dependent RNA polymerase
Trial: NCT05193838
Drug: Allopurinol Tablet
RxNorm normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
Trial: NCT04994509
Drug: Oral Lenacapavir (LEN)
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT04994509
Drug: Subcutaneous (SC) Lenacapavir (LEN)
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injections
Trial: NCT04994509
Drug: F/TAF
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally
Trial: NCT04994509
Drug: F/TDF
RxNorm normalized name: Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT04994509
Drug: PTM Oral LEN
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05118789
Drug: NVL-520
RxNorm normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet of NVL-520
Trial: NCT06315881
Drug: Nicotine Oral Pouch
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insert low FBN R/S ONP
Trial: NCT06315881
Drug: Nicotine Oral Pouch
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insert low FBN \> 99% S ONP
Trial: NCT06315881
Drug: Nicotine Oral Pouch
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insert high R/S ONP
Trial: NCT06315881
Drug: Nicotine Oral Pouch
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insert high FBN \> 99% ONP
Trial: NCT06315881
Drug: Smokeless Tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insert ST
Trial: NCT04869137
Drug: Lenvatinib Oral Product
RxNorm normalized name: lenvatinib Oral Product
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg of Lenvatinib will be taken orally once daily
Trial: NCT04869137
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
Trial: NCT05667805
Drug: Prothrombin Complex Concentrate
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal use (standard treatment)
Trial: NCT05021562
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib capsules
Trial: NCT05577910
Drug: Topical eye drops (Hypromellose, 3mg/ml)
RxNorm normalized name: Soothe Lubricant Eye Drops
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
Trial: NCT06087263
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by PO
Trial: NCT05145361
Drug: B001 injection
DrugBank: KB001 (DB05222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B001 injection 50mg/5mL Intravenous solution
Trial: NCT05500417
Drug: ALFQ
RxNorm normalized name: ALFQ component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
Trial: NCT04517435
Drug: ME-401
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Lactobacillus fermentum (DB16542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
Trial: NCT04517435
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.
Trial: NCT04517435
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 (max 2 mg) IV Vincristine
Trial: NCT04517435
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg PO Prednisone Days 1-5 of 21-day cycle
Trial: NCT04194424
Drug: Metformin Hcl 850Mg Tab
RxNorm normalized name: METFORMIN HCL 850MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet, twice daily
Trial: NCT06654947
Drug: Surufatinib+Toripalimab+GEMOX
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
Trial: NCT06774313
Drug: ABBV-142
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06774313
Drug: ABBV-142
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) Injection
Trial: NCT05008276
Drug: Aminohippurate Sodium Inj 20%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Trial: NCT05008276
Drug: Iohexol Inj 300 MG/ML
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Trial: NCT05008276
Drug: Dextran 40
RxNorm normalized name: Dextran 40
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure glomerular size and selectivity
Trial: NCT06675955
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab will be administered according to the regimen in the parent study.
Trial: NCT04520217
Drug: 4% Imipramine Cream
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4% Imipramine Cream
Trial: NCT04520217
Drug: Base Cream
RxNorm normalized name: U-Base Cream
DrugBank: K201 free base (DB02929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base Cream
Trial: NCT06284941
Drug: Ropivacaine combined with methylene blue for iliac fascia block
RxNorm normalized name: Methylene Blue
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
Trial: NCT06349473
Drug: SR604
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SR604 will be administered as SC injection.
Trial: NCT05661682
Drug: Tralement
RxNorm normalized name: Tralement
DrugBank: Manganese cation (DB06757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralement with Manganese Sulfate
Trial: NCT04729387
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
Trial: NCT04729387
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
Trial: NCT04729387
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
Trial: NCT05071352
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Trial: NCT04086485
Drug: Lu-177-DOTATATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
Trial: NCT04086485
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
Trial: NCT04086485
Drug: Amino Acid infusion
RxNorm normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
Trial: NCT04779697
Drug: GLP-1 analogue - semaglutide
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) analogues
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
Trial: NCT04652960
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05602636
Drug: bupivacaine, midazolam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
Trial: NCT05777226
Drug: Epalrestat
RxNorm normalized name: Epalrestat
DrugBank: Epalrestat (DB15293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the treatment group are intervened with Epalrestat tablets.
Trial: NCT06734273
Drug: Mounjaro
RxNorm normalized name: Mounjaro
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
Trial: NCT06609005
Drug: INV-9956
RxNorm normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
Trial: NCT05849298
Drug: Piflufolastat F 18
RxNorm normalized name: piflufolastat F 18
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
Trial: NCT05849298
Drug: ARPI
RxNorm normalized name: Akarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
Trial: NCT06234631
Drug: Epidiolex oral solution
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening.
Trial: NCT05197530
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
Trial: NCT06091124
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Trial: NCT06091124
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Trial: NCT06091124
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Trial: NCT06773026
Drug: Sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
Trial: NCT06063746
Drug: Vidutolimod
RxNorm normalized name: Vidutolimod
DrugBank: Vidutolimod (DB17500)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05062980
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
Trial: NCT05062980
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
Trial: NCT05062980
Drug: ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
Trial: NCT04965155
Drug: Isatuximab-dexamethasone
RxNorm normalized name: Isatuximab
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
Trial: NCT05525572
Drug: Autologous Platelet-Rich Plasma (PRP)
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval.
Trial: NCT05607004
Drug: (Z)-endoxifen
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Trial: NCT05607004
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exemestane tablets 25 mg
Trial: NCT05607004
Drug: goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: goserelin 3.6 mg subcutaneous implant
Trial: NCT05111600
Drug: Transplantation
RxNorm normalized name: Transplantation antigen
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
Trial: NCT06523556
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT06430580
Drug: Yohimbine Hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54mg yohimbine hcl, single oral dose
Trial: NCT06430580
Drug: Cornstarch Placebo 20mg
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg cornstarch placebo, single oral dose
Trial: NCT06430580
Drug: Cornstarch Placebo 54mg
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54mg cornstarch placebo, single oral dose
Trial: NCT05971602
Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Trial: NCT05971602
Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
Trial: NCT05971602
Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
Trial: NCT05971602
Drug: Isoniazid and Rifampicin (HR)
RxNorm normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
Trial: NCT04846452
Drug: Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
Trial: NCT04846452
Drug: Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
Trial: NCT05862012
Drug: ISB 2001
RxNorm normalized name: ISB 2001
DrugBank: ISB 2001 (DB18570)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive escalating doses of ISB 2001
Trial: NCT05862012
Drug: ISB 2001
RxNorm normalized name: ISB 2001
DrugBank: ISB 2001 (DB18570)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive injection of ISB 2001 as determined in Part 1.
Trial: NCT05059223
Drug: AXS-12 (reboxetine)
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AXS-12 tablets, taken twice daily